Low dietary zinc intake attenuates the efficacy of 2,4-thiazolidinedione on reducing hyperglycemia in db/db mice
(Short communication)

Y-M Song¹, H-Y Hsu², M-D Chen¹,³

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
²Department of Industrial Management, Overseas Chinese University, Taichung, Taiwan
³General Education Center, Overseas Chinese University, Taichung, Taiwan

Received: July 16, 2014
Accepted: July 31, 2015

Zinc (Zn) has the potential of regulating the action of thiazolidinedione (TZD), an anti-diabetic drug. Since some diabetic patients cannot achieve optimal glycemic control when receiving TZD, we investigated if Zn deficiency affects TZD’s efficacy in glucose metabolism. Diabetic mice were fed diets containing 3 or 30 mg/kg Zn for 6 weeks. Thereafter, all mice were oral gavaged with 2,4-thiazolidinedione. Our results showed that blood glucose values at fasting and during the glucose tolerance test were significantly higher in low-Zn mice than those of adequate-Zn mice. Thus, low Zn intake may attenuate TZD’s efficacy on reducing diabetic hyperglycemia.

Keywords: db/db mice, hyperglycemia, NIDDM, thiazolidinedione, zinc deficiency

Type 2 diabetes mellitus has become a serious public health problem worldwide (13). The pivotal mediator for the various manifestations of diabetic complications, including cardiovascular disorders, may be attributed to the oxidative stress derived from factors like hyperglycemia and inflammatory response (2). Zinc (Zn) closely participates in the metabolism of carbohydrate, protein and fat (7). Its deficiency causes a variety of physiological defects, such as growth retardation, immune depression, and acrodermatitis, etc (10). However, reduced Zn intake has become prevalent in many countries (18). Zn also plays an important role in mediating the production and signaling of insulin (17). Diabetic subjects usually have hypozincemia and hyperzincuria, and correction of the Zn status has been proposed as a therapeutic option for diabetic patients (6).

Peroxisome proliferators-activated receptor (PPAR) can act as transcription factor to regulate the activity of various genes, such as nuclear factor kappa B (NF-κB) (12). Although the full pharmacological mechanisms remain unclear, PPAR agonists, of note the thiazolidinediones (TZDs) have been widely administered as an insulin sensitizer to type 2 diabetic patients (12). However, these TZDs have been withdrawn or under restriction due to...
the increased risk of hepatitis (troglitazone), bladder cancer (pioglitazone), and cardiovascular events (rosiglitazone), respectively. Upon re-evaluation of new data in 2013, the US-FDA lifted the restriction on prescribing rosiglitazone.

Zn is known as an essential constituent of PPARs (4). Furthermore, Zn deficiency reduces anti-inflammatory activity of TZD, and the decrease is reversed after Zn repletion (8, 11). In clinical practice, some diabetic patients cannot achieve optimal glycemic control when given TZD therapy (5). The failure of TZD therapy may be associated with the intrinsic difference in adiposity among patients, which is complicated by TZD’s effect on adipocyte differentiation and altered production of adipokines (16). It also seems reasonable to suppose that some patients with TZD inefficacy may have Zn deficiency. The purpose of this preliminary study was to examine if low dietary Zn intake attenuates the efficacy of 2,4-thiazolidinedione on reducing diabetic hyperglycemia.

Materials and Methods

Weanling male db/db mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The db/db mouse, characterized by hyperglycemia, hyperinsulinemia, and leptin-resistant obesity, closely resembles the metabolic profile of type 2 diabetes mellitus. Mice at 5 weeks of age were assigned to diet with low (3 mg/kg) or adequate (30 mg/kg) Zn. Each group contained 7 mice. Diets were prepared as in a previous study (15). Throughout the study, all mice had free access to diet and deionized water.

At the end of a 6-week Zn treatment period, fasting blood samples were obtained by tail cutting from all mice. Circulating concentrations of glucose, insulin, and Zn were measured. Thereafter, without changing their original Zn treatment, all mice were given 2,4-thiazolidinedione (30 mg/kg BW/d, Sigma, St. Louis, MO, USA) for a further week by oral gavage. After completion of 2,4-thiazolidinedione administration, mice were fasted for 6 h and subjected to the oral glucose tolerance test (1 g glucose/kg BW) by following the method described previously (1). A protocol for animal care procedure was approved by the OCU Research Management and Review Committee (Ocit-RD-99A-061).

Body fat content was determined by a body composition analyzer (EM-SCAN Inc., Springfield, IL, USA). Glucose level was measured with a blood glucose meter (Lifescan Surestep, Johnson & Johnson, Milpitas, CA, USA). Insulin measurement (Crystal Chem Inc., Chicago, IL, USA) was performed by enzyme-linked immunoabsorbent assay. Zn concentration was determined by an atomic absorption spectrophotometer (Instrumentation Lab., Wilmington, MA, USA).

All measurements were done on all 7 mice in each group, and the data were presented as the mean ± SD. Statistical analyses of the results were conducted by ANOVA and unpaired Student’s t-test with a commercial package, KaleidaGraph 3.6 for Macintosh. The difference was considered to be significant when P value was < 0.05.

Results

Our data showed that the mice fed low-Zn diet (LZ) had significantly decreased body weight and body fat but similar diet consumption when compared with mice with adequate Zn intake (AZ). LZ mice also had significantly higher glucose (36%) and lower insulin (47%) compared to that of AZ mice (Table I).
Table I. Effects of dietary zinc treatment for 6 weeks on food intake, body weight, body fat, and determined plasma variables in db/db mice

<table>
<thead>
<tr>
<th></th>
<th>AZ group (n = 7)</th>
<th>LZ group (n = 7)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food intake (g)</td>
<td>5.8 ± 1.0</td>
<td>4.9 ± 1.3</td>
<td>0.173</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>33.5 ± 2.4</td>
<td>28.3 ± 3.6</td>
<td>0.010</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>34.2 ± 4.7</td>
<td>25.6 ± 3.5</td>
<td>0.003</td>
</tr>
<tr>
<td>Glucose (mM)</td>
<td>18.2 ± 3.0</td>
<td>24.7 ± 5.2</td>
<td>0.019</td>
</tr>
<tr>
<td>Insulin (pM)</td>
<td>6294 ± 1006</td>
<td>3316 ± 785</td>
<td>0.001</td>
</tr>
<tr>
<td>Zinc (μM)</td>
<td>13.3 ± 2.7</td>
<td>12.0 ± 5.1</td>
<td>0.546</td>
</tr>
</tbody>
</table>

Mean ± SD. AZ group: adequate zinc diet (30 mg/kg); LZ group: low zinc diet (3 mg/kg)

After completion of 2,4-thiazolidinedione administration, fasting blood glucose values of both groups were decreased, though to a less extent in LZ mice, than those at pre-administration period (AZ mice: from 18.2 ± 3.0 to 12.9 ± 2.2 mM, P = 0.004; LZ mice: from 24.7 ± 5.2 to 20.0 ± 4.6 mM, P = 0.100). LZ mice also exhibited impaired glucose tolerance, as manifested by higher blood glucose levels at 30 and 60 min after the glucose load (Fig. 1), resulting in a 39% increase in the AUC (area under curve in glucose challenge test) for glucose (1532 ± 408 vs 1100 ± 147 mM, P = 0.030).

![Fig. 1. Effects of 2, 4-thiazolidinedione treatment (30 mg/kg/d) for a week on blood glucose levels after the administration of the glucose load (1 g glucose/kg, ip) in db/db mice fed diets with 30 mg/kg Zn (AZ) or 3 mg/kg Zn (LZ). Data are expressed as mean ± SD. There is significant difference (*: P < 0.05, **: P < 0.01) between groups at the same sampling time](image)

Discussion

Consistent with previous studies (6, 15), low Zn intake markedly increased glucose and decreased insulin in db/db mice. Since Zn mediates the production of insulin (17), higher glucose and lower insulin observed in db/db mice fed low Zn diet might be attributed to Zn-deficiency-induced reduction in insulin availability. Moreover, Zn deficiency worsened
peripheral glucose utilization and lipogenesis which result in the reduction in body weight and body fat accumulation (15). However, whether Zn-deficiency-induced exacerbation of diabetic hyperglycemia is primarily due to the change in insulin synthesis, or its peripheral clearance, or other causes such as tissue Zn maldistribution (9), remains to be elucidated.

Extreme Zn deficiency causes anorexia (18). However, according to our experience and previous studies (6, 14, 15), low Zn, but not totally depleted, has no significant influence on the amount of food intake. A pair-fed group of mice was thus not included in this study. During a 7-week period of low Zn treatment, our mice exhibited no obvious disorders, such as skin lesions or growth retardation (assessed by tail length, data not shown). Consistent with previous studies (14, 15) using various Zn doses (0.4 or 5 mg/kg), serum Zn levels did not markedly alter by low Zn intake. Our data indicated that a short-term period (7 weeks) of low dietary Zn treatment (3 mg/kg) did not cause severe Zn deficiency. Circulating Zn status might be able to maintain homeostasis by mobilizing Zn from other peripheral tissues like liver during dietary Zn depletion. Previous studies indeed have shown that Zn concentrations in liver (14) and bone (15) are decreased in mice when fed the Zn-deficient diet. In this study, LZ group also had lower Zn levels in pancreas and epididymal fat, though non-significant, than that of AZ group (pancreas: 23.2 ± 9.0 vs 29.5 ± 7.5; fat: 10.7 ± 2.3 vs 13.1 ± 2.4 μg/g tissue).

Chronic inflammation is crucial for the pathogenesis of obesity-related metabolic dysfunctions, including type 2 diabetes mellitus (2). Excess fat mass causes an elevation in circulating proinflammatory markers, like IL-6, TNFα, and C-reactive protein (3). PPAR is linked to the negative regulation of macrophage activation through inhibition of NF-κB and the induced expression of factors like adiponectin (16). On the other hand, subjects with Zn deficiency are known to catch infections more readily (18). Zn not only participates in humoral immunity by regulating B-cell apoptosis and B-cell response to vaccination, but also affects T helper cells and the cytokines secreted by them, and the activation of natural killer cells (10). Hennig et al. firstly indicated that Zn can modulate PPARs signaling and associated regulation of inflammation reaction (8, 11). Zn deficiency also interacts with rosiglitazone to induce proatherogenic lipid profiles in low-density lipoprotein receptor (LDL-R) KO mice (LDL-R–/–) (14). Although we did not measure circulating cytokines in our mice, the data described above suggest that Zn nutritional state should modulate the pathogenesis of inflammatory diseases. Interestingly, rosiglitazone has no influence on plasma glucose in LDL-R–/– mice regardless of the amount of zinc intake (14). However, we did find that 2,4-thiazolidinedione effectively reduced hyperglycemia in db/db mice, and the efficacy was less in mice with low Zn intake. The discrepancy in glycemic response might be due to the intrinsic feature of experimental mice (db/db: hyperglycemia or LDL-R–/–: normoglycemia), the dose of Zn selected to induce Zn deficiency (3 or 0.4 mg/kg), and the type of TZD (2,4-thiazolidinedione or rosiglitazone) administered. Nevertheless, these data indicate that there is an interaction existing between dietary Zn intake and the activity of PPAR agonists.

In summary, our data confirm that low dietary Zn intake exacerbates hyperglycemia of the db/db mice. Furthermore, low Zn intake, even at no apparent Zn deficient status, could attenuate the efficacy of TZD on reducing diabetic hyperglycemia. Therefore, adequate dietary Zn intake might be critical for diabetic patients when receiving TZD therapy.

Acknowledgement

We thank Yi-Wen Hong for providing laboratory facilities and technical assistance. We declare no conflict of interest.
REFERENCES